Infertility is the inability to conceive despite regular unprotected sexual intercourse for one year.

Male infertility as the sole cause accounts for 20% & 30-40% as a contributory factor to infertility in couples.

Causes include: hypothalamic pituitary disease, primary testicular disease, disorders of sperm transport, genetic disorders, idiopathic infertility, infections, immune system disorders, iatrogenic causes, and chronic illness.

Male%20infertility Diagnosis


Endocrine Evaluation

  • Measure luteinizing hormone (LH), follicle-stimulating hormone (FSH) & testosterone levels
    • Serum free testosterone, LH, prolactin - if total testosterone level was low (<300 ng/mL)
  • Indicated for patients w/ abnormal semen analysis especially if w/ <10 millions/mL sperm concentration, impaired sexual function, or w/ high clinical suspicion for endocrine diseases
  • High serum FSH, LH & normal to low testosterone levels may indicate primary hypogonadism (complete testicular failure, hypergonadotrophic hypogonadism)
  • Patients w/ elevated FSH levels may have spermatogenesis abnormalities
  • Low FSH, LH & testosterone levels indicates hypergonadotropic hypogonadism
  • High prolactin & low testosterone levels may be indicative of a prolactin-secreting pituitary tumor


  • To be able to identify correctable causes of male infertility, irreversible causes that can be managed by assisted reproductive techniques, life-threatening conditions underlying infertility, & genetic causes that may affect the offspring in the future
  • Evaluation may be done before 1 year into the marriage & w/ unprotected intercourse if male partner is w/ known history of bilateral cryptorchidism, if female partner is at risk of infertility, especially if >35 years of age, or to confirm the male partner’s fertility potential
Indications for Evaluation
  • Inability to achieve spontaneous pregnancy after >12 months of regular unprotected sexual intercourse
  • If female partner >35 years of age has not conceived after 6 months of regular vaginal intercourse w/o contraceptive interventions
Endocrine/Systemic Disease
  • 80-90% infertile men has primary or secondary hypogonadism, caused by either sperm production impairment/dysfunction, impaired spermatogenesis, or androgen deficiency
Primary Hypogonadism (Testicular Origin)
  • Low testosterone level w/ increased follicle-stimulating hormone (FSH) &  luteinizing hormone (LH) suggest a testicular failure origin for hypogonadism
  • Disorders associated w/ primary hypogonadism include:
  • Congenital disorders: Klinefelter syndrome, Prader-Willi syndrome, familial cerebellar ataxia, Lowe oculocerebellar syndrome
  • Acquired disorders: tumors, infiltrative diseases (eg fungal infections, sarcoidosis, tuberculosis, mumps orchitis), lymphocytic hypophysitis, hepatic cirrhosis, chronic renal failure, radiation, testicular torsion, autoimmune damage, alkylating agents, Ketoconazole, glucocorticoids
Secondary Hypogonadism (Hypothalamic-Pituitary Origin)
  • Low testosterone level w/ decreased FSH & LH is suggestive of a hypothalamic-pituitary origin of disease
  • Disorders associated w/ secondary hypogonadism include Kallmann’s syndrome, DAX-1 & GPR54 mutations, Prader Willi, leptin or leptin receptor mutation, gonadotropin subunit mutation, craniopharyngioma, empty sella syndrome, fractures located at the base of the skull, hyperprolactinemia

Androgen Deficiency

  • Testicular feminisation & Reifenstein syndrome causes androgen resistance
Idiopathic Hypogonadotropic Hypogonadism
  • Presence of low testosterone/FSH/LH levels even w/o existing anatomical or functional defects in the hypothalamic-pituitary-gonadal axis
Please refer to Hypogonadism in Males - Late-Onset Disease Management Chart for more information
  • Male urogenital tract infection includes infection in the testis, prostate, epididymal ducts & urethra & other structures where semen passes through
  • Chronic infections causing an increase in leukocytes in the ejaculate may decrease sperm quality, inflammation may cause partial genital tract obstruction
  • Past genital infections (ie gonorrhea, STDs) w/c may cause epididymal & vas obstruction, & history of mumps & orchitis may cause sterility
Please refer to Urinary Tract Infection - Complicated Disease Management Chart for more information
Semen Autoimmunity
  • Present in 4-6% of infertile men
  • Presence of sperm antibodies result in decreased motility & impaired sperm-cervical mucus penetration
Post-Testicular Dysfunction
  • Affects 15-20% of men w/ infertility
Anatomical Obstruction
  • Obstruction in the testicular ducts, epididymis, vas deferens, ejaculatory duct, seminal ducts may cause obstructive azoospermia
  • Investigations for obstruction should be considered for azoospermic or severely oligozoospermic men w/ normal-sized testes & normal endocrine evaluation results
  • Intratesticular obstruction may be caused by an obstruction in the seminiferous tubules or w/in the rete testis
    • Accounts for 15% of men w/ obstructive azoospermia
  • Epididymal obstruction accounts for 30-67% of infertile men w/ obstructive azoospermia
  • Obstruction of the vas deferens is the most common cause of acquired obstruction after vasectomy or hernia repair
    • Congenital bilateral aplasia of vas deferens (CBAVD) is the most common congenital cause of vas deferens obstruction
  • Ejaculatory duct obstruction, caused by either cystic formation or post-infectious fibrosis, accounts for 1-3% of infertility in men w/ obstructive azoospermia
  • Abnormal enlargement or dilatation of the spermatic veins in the pampiniform plexus of the scrotum w/ a diameter increase of >0.3 mm during Valsalva maneuver
  • Accompanied by ipsilateral testicular growth/development failure, pain, male subfertility & hypogonadism
  • Classification:
    • Subclinical - not visible; not evident upon palpation; positive in Doppler ultrasound detection
    • Grade I - not visible; palpable only w/ Valsalva maneuver
    • Grade II - not visible; palpable w/o Valsalva maneuver
    • Grade III - visible through the scrotum; palpable at rest
  • Most common congenital male genital abnormality that may be caused by disruption of endocrine regulation or gene defects
  • Affects 2-5% of newborn male babies, resulting to impaired semen parameters ie low sperm count & quality
  • Severity depends on the duration of suprascrotal location of the testes
  • Low serum inhibin B & increased FSH level indicates high risk for infertility
  • Men w/ history of cryptorchidism are at increased risk for testicular cancer
Sexual Dysfunction
  • Includes erectile dysfunction, anorgasmia, delayed ejaculation, retrograde ejaculation, aesthenic ejaculation, premature ejaculation, & mechanical obstruction (condom, diaphragm)
  • May be caused by problems in ejaculation from spinal cord trauma/disease or autonomic disease
Premature Ejaculation
  • Short, involuntarily controlled, easily stimulated ejaculation that occurs always or nearly always before or w/in 1 minute of vaginal penetration or a clinically significant & bothersome reduction in latency time, often to about 3 minutes or less in patients w/ premature ejaculation
  • Either present from the first sexual experience or following a new bothersome change in ejaculatory latency
  • Causes negative personal consequences (eg distress, bother, frustration, avoidance of sexual intimacy & interpersonal difficulty)
Delayed ejaculation or Anejaculation
  • Persistent or recurrent delay in, or absence of, orgasm after a normal sexual excitement phase during sexual activity
  • Disturbance causes marked distress or interpersonal difficulty & can be a lifelong or an acquired problem
  • Hypogonadism, low testosterone levels, hypothyroidism & hyperprolactinemia are all associated w/ delayed ejaculation
  • Testicular germ cell tumor may manifest as low sperm quality prior to diagnosis, w/c may be due to spermatogenic failure& Leydig cell dysfunction
    • Hypogonadism & sexual dysfunction may occur after treatment
  • Cryptorchidism, hypospadias, & dysgenic testis increases the risk for testicular cancer
Testicular Microlithiasis
  • Intratesticular hyperechogenic lesions w/o shadowing measuring <3 mm in diameter
  • Commonly seen in men w/ testicular germ cell tumor, cryptorchidism, testicular dysgenesis, testicular torsion & atrophy, Klinefelter’s syndrome, hypogonadism, epididymal cysts, etc
Genetic Disorders
Cystic Fibrosis Gene Mutations
  • Most common cause of congenital bilateral absence of the vasa diferentia (CBAVD)
  • Patient usually presents w/ low semen volume & nonpalpable vasa
  • Caused by a defect in the CFTR gene
  • Patients w/ this condition should also be evaluated for seminal vesicle hypoplasia or agenesis
  • Additional imaging studies of the renal system is suggested for patients w/ unilateral vasal agenesis & congenital bilateral absence of the vasa diferentia but w/o CFTR gene abnormalities
  • Gene sequencing should also be considered if the female partner is a CFTR gene defect carrier & male partner is positive for CFTR gene mutations
Chromosomal Abnormalities
  • Affects 10-15% azoospermic men, 5% men w/ severe oligozoospermia, & 1% men w/ normal sperm volumes
  • Klinefelter’s syndrome accounts for 2/3 of infertile men w/ chromosomal abnormalities & therefore the most common cause of primary hypogonadism
  • Most common autosomal chromosome abnormalities include Robertsonian translocations, reciprocal translocations, paracenteric inversions, & marker chromosomes
Y-Chromosome Microdeletions
  • Affects 5-7% of infertile men w/ severe impaired spermatogenesis, 16% azoospermic or severely oligozoospermic men
    • Increases as testicular deficiency increases
  • The specific deletion on the long arm of the Y chromosome determines the effect on spermatogenesis
    • AZFc deletions, the most common type, causes azoospermia or severe oligozoospermia
    • AZF deletions transmission to male offspring is guaranteed
    • Y-chromosome gr/gr deletion removes 1/2 of the genes in the AZFc region, significantly increasing the risk for oligozoospermia by 2.5-8 fold
  • Inherited disorders w/ known disorders in fertility include Prader-Willi syndrome, Bardet-Biedl syndrome, Noonan’s syndrome, myotonic dystrophy, 5-a reductase deficiency, etc
Genetic Defects
  • Includes x-linked genetic disorders, Kallman syndrome, mild androgen insensitivity syndrome, & other X-linked disorders
  • Kallman syndrome patients present w/ hypogonadotropic hypogonadism
  • Clinical presentation of patients w/ androgen insensitivity syndrome depends on its severity
    • Mild: asymptomatic; diagnosed only upon work-up for male infertility
    • Complete: female external genitalia w/ absent pubic hair (Morris syndrome)
    • Partial (Reifenstein syndrome): female phenotype w/ ambiguous genitalia, or male phenotype w/ micropenis, perineal hypospadias, & cryptorchidism


Medical History
  • Obtain the patient’s complete review of systems, family reproductive history, & social history (include use of anabolic steroids, recreational drugs, smoking, & alcohol history)
Reproductive History
  • Includes coital frequency & timing, duration of infertility, previous fertility, childhood/developmental medical history, systemic disease history, previous surgery, past & present medications, history of allergies, sexual history including STDs, gonadotoxin exposure

Physical Examination

  • Should include an examination of the following:
    • Penis - palpate, & include inspection of the urethral meatus
    • Testis - measurement & palpation
    • Vas deferens & epididymis - palpate for presence of nodules or masses, inspect for enlargement
  • Note for the presence of varicoceles, gynecomastia, & secondary sexual characteristics
  • A digital rectal exam may be performed as necessary

Laboratory Tests

Sperm Analysis
  • Primary test for male infertility
  • Used to evaluate the severity of infertility
  • Initially, two sperm analysis taken 1 month apart is recommended
  • Repeat sperm analysis 3 months after initial test if 1st analysis is abnormal (earlier if abnormality is due to azoospermia or severe oligozoospermia)
Sperm Analysis: Lower Limits of Accepted Reference Values


    Reference values

    Ejaculate volume

    1.5 mL



    Sperm concentration

    15 x 106 spermatozoa/mL

    Total sperm number

    39 x 106 spermatozoa/ejaculate

    Percentage motility


    Forward progression


    Normal morphology

    4% normal


    58% live spermatozoa

    Sperm agglutination



    2 cm thread after liquefaction

Adapted from: Cooper TG, Noonan E, von Eckardstein S, et al. WHO reference values for human semen characteristics. 2010.
Specialized Semen/Sperm Tests
  • Quantification of leukocytes in semen
    • Increased leukocyte count (>106 wbc/mL) may indicate presence of genital infection leading to poor semen function & motility
  • Antisperm antibodies (ASA) tests
  • Eg immunobead test (IBT), mixed antiglobulin reaction
    • ASA appears as a result of a breach in the blood-testis barrier, sperm antigen exposure, or post-vasectomy especially in patients w/ history of trauma, torsion, biopsy, orchitis, & testicular carcinoma
    • Should not be routinely offered, as more studies are needed to confirm its benefit in the evaluation of male infertility
    • May be indicated for patients w/ isolated asthenospermia or sperm agglutination on sperm analysis
    • Presence of surface antibodies may result in spermatozoal failure in cervical mucus penetration
  • Semen culture
    • May be considered for samples w/ presence of inflammatory cells
  • Fluorescent In Situ Hybridization (for sperm DNA aneuploidy testing)
  • Sperm viability tests
    • Used to determine the viability of nonmotile sperm by examining the sperm’s cell membranes
  • Sperm DNA fragmentation tests
    • Helps identify sperm DNA damage & integrity that may affect a couple’s reproductive performance or an embryo’s development
  • Other testing: sperm penetration assays, sperm creatine kinase measurement, sperm-cervical mucus interaction
Post-ejaculatory Urinalysis
  • An ejaculate volume of <1 mL signifies the need for post-ejaculatory urinalysis
  • Done to rule out retrograde ejaculation, except for those w/ hypogonadism, congenital bilateral absence of the vasa diferentia (CBAVD)
Testicular Biopsy
  • Helps identify patients w/ obstructive azoospermia suspected of having acquired seminal duct obstruction & to exclude those w/ spermatogenic failure
  • May be considered w/ the intention of obtaining sperm for cryopreservation (for assisted reproductive techniques)
  • Obtaining >1 biopsy sample is recommended
  • 50% of men w/ non-obstructive azoospermia is positive for spermatozoa upon extraction


  • Used for the detection of scrotal or penile pathologies
Scrotal ultrasound
  • Mandatory test in male infertility, especially those w/ suspected testicular mass
  • Helps detect scrotal pathologies not commonly seen during physical examination (eg varicoceles, tumors, spermatoceles, vas deferens aplasia, testicular microlithiasis, obstruction)
  • Provides better examination of patients w/ testes located in the upper scrotum, small scrotal sac, & other anatomic defects
Transrectal ultrasound (TRUS)
  • Used to diagnose ejaculatory duct obstruction in patients w/ azoospermia, palpable vasa, low ejaculate volume, & normal testicular size
Penile ultrasound
  • Helps detect penile pathologies ie hypospadia, phimosis
  • Radiographic examination used to identify the presence of sperm in the vasal fluid & obstruction w/in the seminal vesicles, epididymis, vas deferens, or ejaculatory duct
  • Indications:
    • Absolute indications - azoospermia plus complete spermatogenesis & numerous mature spermatids on biopsy plus at least 1 palpable vas
    • Relative indications - severe oligospermia but normal on testicular biopsy, increased sperm-bound antibodies, low semen volume, sperm motility grades 0-2
Other Imaging Modalities
  • Magnetic resonance imaging (MRI) & computed tomography (CT) scan may be considered in patients w/ hypogonadism suspected to be caused by a tumor


Genetic Screening
  • Recommended for patients w/ non-obstructive azoospermia & severe oligospermia (<5 million sperm/mL) (eg karyotype abnormalities, Y-chromosome microdeletions, cystic fibrosis transmembrane conductance regulating [CFTR] gene)
  • Karyotype analysis is recommended for men w/ azoospermia or oligospermia of <10 million/mL
  • Indications for Y-chromosome testing include azoospermia & severe oligozoospermia
Editor's Recommendations
Most Read Articles
07 May 2021
Both denosumab and alendronic acid fall short of reducing disease progression in patients with calcific aortic stenosis, a study has shown.
01 Apr 2021
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.
Elvira Manzano, 06 May 2021
An investigational transdermal amphetamine patch worn for 9 hours on the hip appeared effective in paediatric patients with attention deficit-hyperactivity disorder (ADHD) in a phase II, two-part trial.
08 May 2021
The effect of cannabidiol (CBD) in the treatment of patients with Lennox–Gastaut syndrome may occur within 7 days of initiation, and most adverse events resolve within a 14-week period, a study reports.